Autologous engineered T Cells therapy targeting KRAS G12D(Neogene Therapeutics)

N/A

Report date: 2024/01/24 20:04:18

Base Information

Drug NameAutologous engineered T Cells therapy targeting KRAS G12D(Neogene Therapeutics)
Drug Alias NameNT-112
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionKRAS G12D modulatorsT lymphocyte replacements
TargetsKRAS G12D
Therapy Area/IndicationsSolid tumoursEndometrial NeoplasmsCarcinoma, Non-Small-Cell Lung +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNeogene Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca Plc
Inactive CompaniesN/A
Active IndicationsSolid tumoursEndometrial NeoplasmsCarcinoma, Non-Small-Cell Lung +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A